These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 30386383)

  • 1. An integrated approach of bioinformatic prediction and in vitro analysis identified that miR-34a targets
    Hajalirezay Yazdi S; Paryan M; Mohammadi-Yeganeh S
    Cell Mol Biol Lett; 2018; 23():51. PubMed ID: 30386383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA.
    Mackiewicz M; Huppi K; Pitt JJ; Dorsey TH; Ambs S; Caplen NJ
    Breast Cancer Res Treat; 2011 Nov; 130(2):663-79. PubMed ID: 21814748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA 34a-AXL Axis Regulates Vasculogenic Mimicry Formation in Breast Cancer Cells.
    Lim D; Cho JG; Yun E; Lee A; Ryu HY; Lee YJ; Yoon S; Chang W; Lee MS; Kwon BS; Kim J
    Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33374832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of
    Pishkari S; Hadavi R; Koochaki A; Razaviyan J; Paryan M; Hashemi M; Mohammadi-Yeganeh S
    Horm Mol Biol Clin Investig; 2021 Mar; 42(3):265-271. PubMed ID: 33769725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism.
    El Bezawy R; De Cesare M; Pennati M; Deraco M; Gandellini P; Zuco V; Zaffaroni N
    J Hematol Oncol; 2017 Jan; 10(1):19. PubMed ID: 28100259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-34a suppresses ovarian cancer proliferation and motility by targeting AXL.
    Li R; Shi X; Ling F; Wang C; Liu J; Wang W; Li M
    Tumour Biol; 2015 Sep; 36(9):7277-83. PubMed ID: 25895459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wnt pathway targeting reduces triple-negative breast cancer aggressiveness through miRNA regulation in vitro and in vivo.
    Mohammadi-Yeganeh S; Hosseini V; Paryan M
    J Cell Physiol; 2019 Aug; 234(10):18317-18328. PubMed ID: 30945294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer.
    Mudduluru G; Ceppi P; Kumarswamy R; Scagliotti GV; Papotti M; Allgayer H
    Oncogene; 2011 Jun; 30(25):2888-99. PubMed ID: 21317930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Axl-Regulating Tumor Suppressor miR-34a Is Increased in ccRCC but Does Not Correlate with Axl mRNA or Axl Protein Levels.
    Fritz HK; Gustafsson A; Ljungberg B; Ceder Y; Axelson H; Dahlbäck B
    PLoS One; 2015; 10(8):e0135991. PubMed ID: 26287733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Negative feedback regulation of AXL by miR-34a modulates apoptosis in lung cancer cells.
    Cho CY; Huang JS; Shiah SG; Chung SY; Lay JD; Yang YY; Lai GM; Cheng AL; Chen LT; Chuang SE
    RNA; 2016 Feb; 22(2):303-15. PubMed ID: 26667302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-34a inhibits cell invasion and epithelial-mesenchymal transition via targeting AXL/PI3K/AKT/Snail signaling in nasopharyngeal carcinoma.
    Jiang C; Cheng Z; Jiang T; Xu Y; Wang B
    Genes Genomics; 2020 Aug; 42(8):971-978. PubMed ID: 32648233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism research of miR-34a regulates Axl in non-small-cell lung cancer with gefitinib-acquired resistance.
    Xiong R; Sun XX; Wu HR; Xu GW; Wang GX; Sun XH; Xu MQ; Xie MR
    Thorac Cancer; 2020 Jan; 11(1):156-165. PubMed ID: 31777195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer-associated fibroblasts contribute to oral cancer cells proliferation and metastasis via exosome-mediated paracrine miR-34a-5p.
    Li YY; Tao YW; Gao S; Li P; Zheng JM; Zhang SE; Liang J; Zhang Y
    EBioMedicine; 2018 Oct; 36():209-220. PubMed ID: 30243489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated analysis of mRNA and miRNA profiles revealed the role of miR-193 and miR-210 as potential regulatory biomarkers in different molecular subtypes of breast cancer.
    Evangelista AF; Oliveira RJ; O Silva VA; D C Vieira RA; Reis RM; C Marques MM
    BMC Cancer; 2021 Jan; 21(1):76. PubMed ID: 33461524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of miRNAs expression in medullary thyroid carcinoma tissue samples: miR-34a and miR-144 as promising overexpressed markers in MTC.
    Shabani N; Razaviyan J; Paryan M; Tavangar SM; Azizi F; Mohammadi-Yeganeh S; Hedayati M
    Hum Pathol; 2018 Sep; 79():212-221. PubMed ID: 29885402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coordinated regulation of WNT/β-catenin, c-Met, and integrin signalling pathways by miR-193b controls triple negative breast cancer metastatic traits.
    Giacomelli C; Jung J; Wachter A; Ibing S; Will R; Uhlmann S; Mannsperger H; Sahin Ö; Yarden Y; Beißbarth T; Korf U; Körner C; Wiemann S
    BMC Cancer; 2021 Dec; 21(1):1296. PubMed ID: 34863149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.
    Pénzes K; Baumann C; Szabadkai I; Orfi L; Kéri G; Ullrich A; Torka R
    Cancer Biol Ther; 2014; 15(11):1571-82. PubMed ID: 25482942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hsa_circ_0000199 facilitates chemo-tolerance of triple-negative breast cancer by interfering with miR-206/613-led PI3K/Akt/mTOR signaling.
    Li H; Xu W; Xia Z; Liu W; Pan G; Ding J; Li J; Wang J; Xie X; Jiang D
    Aging (Albany NY); 2021 Jan; 13(3):4522-4551. PubMed ID: 33495420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TGFβ1 regulates HGF-induced cell migration and hepatocyte growth factor receptor MET expression via C-ets-1 and miR-128-3p in basal-like breast cancer.
    Breunig C; Erdem N; Bott A; Greiwe JF; Reinz E; Bernhardt S; Giacomelli C; Wachter A; Kanthelhardt EJ; Beißbarth T; Vetter M; Wiemann S
    Mol Oncol; 2018 Sep; 12(9):1447-1463. PubMed ID: 30004628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-141 as potential suppressor of β-catenin in breast cancer.
    Abedi N; Mohammadi-Yeganeh S; Koochaki A; Karami F; Paryan M
    Tumour Biol; 2015 Dec; 36(12):9895-901. PubMed ID: 26164002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.